Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 40,000 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total transaction of $217,200.00. Following the transaction, the insider now owns 1,353,510 shares of the company's stock, valued at approximately $7,349,559.30. This represents a 2.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Xeris Biopharma Stock Performance
NASDAQ XERS remained flat at $5.87 on Tuesday. 4,682,702 shares of the company's stock traded hands, compared to its average volume of 1,671,096. The company has a market capitalization of $903.63 million, a price-to-earnings ratio of -13.04 and a beta of 2.32. The stock's fifty day simple moving average is $3.93 and its 200-day simple moving average is $3.44. Xeris Biopharma Holdings, Inc. has a 1 year low of $1.69 and a 1 year high of $5.97.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of XERS. NewEdge Advisors LLC acquired a new stake in shares of Xeris Biopharma in the fourth quarter valued at about $34,000. R Squared Ltd acquired a new stake in Xeris Biopharma during the 4th quarter valued at approximately $42,000. Cibc World Markets Corp bought a new position in Xeris Biopharma during the 4th quarter worth approximately $44,000. Raymond James Financial Inc. acquired a new position in shares of Xeris Biopharma in the 4th quarter worth approximately $45,000. Finally, Two Sigma Advisers LP bought a new stake in shares of Xeris Biopharma in the 4th quarter valued at $47,000. 42.75% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of research firms have issued reports on XERS. Leerink Partners lifted their target price on Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a research report on Friday, March 7th. Piper Sandler reaffirmed a "neutral" rating and set a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. HC Wainwright reissued a "buy" rating and issued a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Jefferies Financial Group reaffirmed a "buy" rating and set a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Finally, Craig Hallum increased their price target on Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a research note on Friday, March 7th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Xeris Biopharma has a consensus rating of "Moderate Buy" and an average target price of $5.92.
Check Out Our Latest Report on Xeris Biopharma
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Featured Stories
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
